MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Akciju saraksts・Editas Medicine Inc

Editas Medicine Inc

Slēgts

SektorsVeselības aprūpe

2.11 4.46

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.01

Max

2.11

Galvenie mērījumi
By Trading Economics
Ienākumi	28M -25M
Pārdošana	4M 7.5M
Peļņas marža	-332.984
Darbinieki	246
EBITDA	27M -22M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+99.01% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-77M 198M
Iepriekšējā atvēršanas cena	-2.35
Iepriekšējā slēgšanas cena	2.11

Ziņu noskaņojums

By Acuity

50%

177 / 360 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.33 / 1.54 Atbalsts un pretestība

Editas Medicine Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. janv. 23:49 UTC

Galvenie tirgus virzītāji

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026. g. 21. janv. 21:12 UTC

Galvenie tirgus virzītāji

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 21:00 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026. g. 21. janv. 20:29 UTC

Galvenie tirgus virzītāji

Chip Makers Gain After Trump Calls Off European Tariffs

2026. g. 21. janv. 20:04 UTC

Galvenie tirgus virzītāji

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 23:48 UTC

Tirgus saruna

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026. g. 21. janv. 23:34 UTC

Tirgus saruna

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026. g. 21. janv. 22:39 UTC

Peļņas

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 21. janv. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026. g. 21. janv. 21:19 UTC

Peļņas

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026. g. 21. janv. 20:45 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026. g. 21. janv. 20:36 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026. g. 21. janv. 20:31 UTC

Tirgus saruna

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026. g. 21. janv. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Was It a 'TACO' Event? -- Market Talk

2026. g. 21. janv. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026. g. 21. janv. 20:23 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026. g. 21. janv. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026. g. 21. janv. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Group Agrees to Buy Allfunds

2026. g. 21. janv. 20:08 UTC

Peļņas

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026. g. 21. janv. 20:03 UTC

Tirgus saruna

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026. g. 21. janv. 19:51 UTC

Tirgus saruna

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026. g. 21. janv. 19:43 UTC

Tirgus saruna

U.S. Ethanol Production Expected to Slip -- Market Talk

2026. g. 21. janv. 19:31 UTC

Tirgus saruna

Gold Settles at Fresh All-Time High -- Market Talk

2026. g. 21. janv. 19:24 UTC

Peļņas

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026. g. 21. janv. 19:10 UTC

Tirgus saruna

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026. g. 21. janv. 18:57 UTC

Tirgus saruna

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Salīdzinājums

Cenas izmaiņa

Editas Medicine Inc Prognoze

Cenas mērķis

By TipRanks

99.01% augšup

Prognoze 12 mēnešiem

Vidējais 4.02 USD 99.01%

Augstākais 5 USD

Zemākais 3 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Editas Medicine Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Editas Medicine Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.33 / 1.54Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Noskaņojums

By Acuity

177 / 360 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.